Corbus Pharmaceuticals Holdings, Inc. (CRBP) Debt Components
- 2024-12-31: Notes Payable, CurrentUSD $0.00; Long-term Debt, GrossUSD $0.00; Debt Instrument, Face AmountUSD $0.00; Debt Instrument, Unamortized DiscountUSD $0.00.
- 2024-09-30: Notes Payable, CurrentUSD $0.00; Long-term Debt, GrossUSD $0.00; Debt Instrument, Face AmountUSD $0.00; Debt Instrument, Unamortized DiscountUSD $0.00.
- 2024-06-30: Notes Payable, CurrentUSD $77.00K; Long-term Debt, GrossUSD $10.74M; Debt Instrument, Face AmountUSD $10.82M; Debt Instrument, Unamortized DiscountUSD $2.95M.
- 2024-03-31: Notes Payable, CurrentUSD $189.82K; Long-term Debt, GrossUSD $12.76M; Debt Instrument, Face AmountUSD $12.97M; Debt Instrument, Unamortized DiscountUSD $2.95M.
Corbus Pharmaceuticals Holdings, Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Notes Payable, Current USD | Long-term Debt, Gross USD | Debt Instrument, Face Amount USD | Debt Instrument, Unamortized Discount USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Notes Payable USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Increase (Decrease), Net USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Periodic Payment USD | Debt Instrument, Convertible, Beneficial Conversion Feature USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | $0.00 | $0.00 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $0.00 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $77.00K | $10.74M | $10.82M | $2.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $189.82K | $12.76M | $12.97M | $2.95M | $12.76M | $0.00 | (m) | (m) | $14.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $301.00K | $15.91M | $16.30M | $2.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | $15.91M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $17.89M | $17.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $17.85M | $18.44M | $2.95M | $17.85M | $0.00 | (m) | $20.03M | $17.89M | (m) | (m) | (m) | $2.13M | (m) | (m) | (m) | (m) |
| 2023-06-30 | $51.16K | $18.34M | $19.12M | $2.95M | $7.02M | $11.32M | (m) | $20.71M | $2.83M | $17.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $203.26K | $18.98M | $20.00M | $2.95M | $5.01M | $13.97M | (m) | $21.59M | $2.96M | $18.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $573.00K |
| 2022-12-31 | $353.32K | $18.78M | $20.00M | $2.95M | $2.80M | $15.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $21.59M | $2.98M | $18.61M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $19.27M | $20.00M | $2.26M | $9.88M | $9.39M | (m) | $21.19M | $9.77M | $8.39M | (m) | (m) | $3.02M | (m) | (m) | (m) | (m) |
| 2022-06-30 | $110.70K | $19.09M | $20.00M | $2.26M | $7.47M | $11.61M | (m) | $21.19M | $9.80M | $8.33M | (m) | (m) | $3.05M | (m) | (m) | (m) | (m) |
| 2022-03-31 | $440.81K | $18.91M | $20.00M | $2.26M | $5.18M | $13.73M | (m) | $21.19M | $9.83M | $8.27M | (m) | (m) | $3.09M | (m) | (m) | (m) | (m) |
| 2021-12-31 | $767.94K | $18.73M | $20.00M | $2.26M | $3.09M | $15.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $21.19M | $3.09M | $9.84M | $8.26M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $18.55M | $20.00M | $2.26M | (m) | $18.55M | (m) | $21.19M | $3.09M | $9.84M | $8.26M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $102.69K | $18.37M | $20.00M | $2.26M | (m) | $18.37M | (m) | $21.19M | $3.09M | $9.84M | $8.26M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $408.28K | $18.20M | $20.00M | $2.26M | (m) | $18.20M | (m) | $21.19M | $3.09M | $9.84M | $8.26M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $710.16K | (m) | (m) | (m) | (m) | $18.03M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $18.03M | $20.00M | $2.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $21.19M | (m) | $3.09M | $9.84M | $8.26M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $17.86M | $20.00M | $2.26M | (m) | $17.86M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $108.94K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $432.90K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $752.66K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $99.33K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $247.38K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $394.31K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $83.70K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $208.65K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $332.86K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $39.04K | (m) | (m) | (m) | (m) | (m) | $39.04K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $155.73K | (m) | (m) | (m) | (m) | (m) | $155.73K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $271.76K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $271.76K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $36.38K | (m) | (m) | (m) |
| 2016-06-30 | $23.33K | (m) | (m) | (m) | (m) | (m) | $23.33K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $36.38K | (m) | (m) | (m) |
| 2016-03-31 | $92.96K | (m) | (m) | (m) | (m) | (m) | $92.96K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $162.02K | (m) | (m) | (m) | (m) | (m) | $162.02K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · $36.38K | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $36.38K | (m) | (m) | (m) |
| 2015-03-31 | $72.49K | (m) | (m) | (m) | (m) | (m) | $72.49K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $144.39K | (m) | (m) | (m) | (m) | (m) | $144.39K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $24.29K | (m) |
| 2014-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3.25% | (m) | (m) |
| 2014-10-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 1 month · $24.29K | (m) |
| 2014-09-30 | $75.24K | (m) | (m) | (m) | (m) | (m) | $75.24K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 7.00% | (m) | (m) |
| 2013-12-31 | $306.83K | (m) | (m) | (m) | (m) | (m) | $638.08K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |